Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo
| العنوان: | Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo |
|---|---|
| المؤلفون: | Raie T. Bekele, Matthew G.K. Benesch, David N. Brindley, Ganesh Venkatraman, Xiaoyun Tang |
| المصدر: | Journal of Biomedical Research |
| بيانات النشر: | Editorial Department of Journal of Biomedical Research, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | 0301 basic medicine, chronic inflammation, Angiogenesis, Phosphatase, Review Article, Biology, General Biochemistry, Genetics and Molecular Biology, Metastasis, 03 medical and health sciences, chemistry.chemical_compound, wound repair, In vivo, medicine, cancer, Receptor, General Medicine, Lipid-phosphate phosphatase, medicine.disease, cytokines, 3. Good health, 030104 developmental biology, Lysophosphatidylcholine, chemistry, Biochemistry, Cancer research, lipids (amino acids, peptides, and proteins), monoclonal antibodies, Autotaxin, biological phenomena, cell phenomena, and immunity |
| الوصف: | Extracellular lysophosphatidate (LPA) is a potent bioactive lipid that signals through six G-protein-coupled receptors. This signaling is required for embryogenesis, tissue repair and remodeling processes. LPA is produced from circulating lysophosphatidylcholine by autotaxin (ATX), and is degraded outside cells by a family of three enzymes called the lipid phosphate phosphatases (LPPs). In many pathological conditions, particularly in cancers, LPA concentrations are increased due to high ATX expression and low LPP activity. In cancers, LPA signaling drives tumor growth, angiogenesis, metastasis, resistance to chemotherapy and decreased efficacy of radiotherapy. Hence, targeting the ATX-LPA-LPP axis is an attractive strategy for introducing novel adjuvant therapeutic options. In this review, we will summarize current progress in targeting the ATX-LPA-LPP axis with inhibitors of autotaxin activity, LPA receptor antagonists, LPA monoclonal antibodies, and increasing low LPP expression. Some of these agents are already in clinical trials and have applications beyond cancer, including chronic inflammatory diseases. |
| اللغة: | English |
| تدمد: | 2352-4685 1674-8301 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855e64b2404c4063e2974538d77ab00bTest http://europepmc.org/articles/PMC4946318Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....855e64b2404c4063e2974538d77ab00b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23524685 16748301 |
|---|